Foghorn Therapeutics Secures $50M in January 2026 Offering, Extends Operating Runway

summarizeSummary

Foghorn Therapeutics reported a $50 million capital raise in January 2026, alongside reduced net losses and cash burn in 2025. The company's lead candidate, FHD-909, advanced into Phase 1 clinical trials, while another program, FHD-286, was discontinued.

check_boxKey Events

• Secured $50 Million in January 2026 Offering

  The company raised approximately $50 million in gross proceeds through the issuance of common stock, pre-funded warrants, and Series 1 and Series 2 warrants. The common stock was offered at $6.71 per share, above the current market price.

• Improved Financial Performance in 2025

  Foghorn Therapeutics reported a net loss of $74.3 million in 2025, a decrease from $86.6 million in 2024. Net cash used in operating activities also decreased to $86.1 million from $100.4 million in the prior year.

• Lead Candidate FHD-909 Enters Phase 1 Trial

  The lead product candidate, FHD-909, a selective SMARCA2 inhibitor, entered a Phase 1 dose escalation trial in October 2024 as part of the collaboration with Eli Lilly and Company.

• Discontinuation of FHD-286 Program

  The independent development of FHD-286 in relapsed/refractory acute myeloid leukemia and uveal melanoma was discontinued in December 2024.

auto_awesomeAnalysis

Foghorn Therapeutics' annual report highlights a critical $50 million capital raise in January 2026, significantly bolstering its financial position. This funding, obtained through a mix of common stock, pre-funded warrants, and Series 1 and Series 2 warrants, is essential for a clinical-stage biotechnology company with ongoing operating losses. The offering price of $6.71 per share for common stock was above the current market price, indicating investor confidence in the company's prospects. The company also reported a reduced net loss and lower cash burn in 2025 compared to 2024, alongside increased collaboration revenue, signaling improved financial management. A key pipeline advancement is the lead candidate FHD-909 entering a Phase 1 trial in October 2024 under the collaboration with Eli Lilly. However, the company discontinued the independent development of FHD-286 in AML and uveal melanoma in December 2024, a pipeline setback that also contributes to reduced R&D expenses. Management expects current cash, cash equivalents, and marketable securities to fund operations for at least the next 12 months, providing a crucial runway for its drug development programs.